Post-Marketing Observational Study of Safety Following Vaccination With Flublok Compared to Licensed IIV in Adults 18 Years of Age and Older
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2016
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Protein Sciences Corporation
- 17 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 17 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 14 Nov 2015 New trial record